10 completed, 1 terminated, 1 unknown. 5 Phase 2, 4 Phase 4, 2 Phase 1, 2 Phase 3.
By phase and status
Follow Trimeris: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients
enfuvirtide [Fuzeon], Optimized background ARV, Integrase inhibitor - HIV Infections | Phase 4 | Terminated | Hoffmann-La Roche | 29 | 2007-06-01 | 2011-07-22 |
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
enfuvirtide [Fuzeon] - HIV Infections | Phase 4 | Completed | Hoffmann-La Roche | 326 | 2006-06-01 | 2015-11-03 |
BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.
Background ARVs, PI, enfuvirtide [Fuzeon] - HIV Infections | Phase 4 | Completed | Hoffmann-La Roche | 142 | 2006-03-01 | 2016-08-16 |
WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV.
enfuvirtide [Fuzeon] - HIV Infections | Phase 4 | Completed | Hoffmann-La Roche | 58 | 2005-08-01 | 2015-11-03 |
A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients
Optimized Background ARVs, enfuvirtide [Fuzeon] - HIV Infections | Phase 2 | Completed | Hoffmann-La Roche | 64 | 2004-07-01 | 2016-11-02 |
T-20 Plus a Selected Anti-HIV Treatment in HIV-Infected Children and Adolescents
Enfuvirtide - HIV Infections | Phase 2 | Completed | Hoffmann-La Roche | 52 | 2001-08-01 | 2016-02-15 |
A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults
Enfuvirtide, Ritonavir, Abacavir sulfate - HIV Infections | Phase 2 | Completed | Hoffmann-La Roche | 68 | 1999-05-01 | 2005-11-15 |
A Rollover Study to Provide Chronic T-1249 to Patients Who Completed Study T1249-102
T-1249 - HIV Infections | Phase 1 / Phase 2 | Unknown | Trimeris | | | 2005-06-24 |
T-20 in HIV Patients With Prior Drug Treatment and/or Resistance to Each of the Three Classes of Anti-HIV Drugs
Enfuvirtide - HIV Infections | Phase 3 | Completed | Hoffmann-La Roche | 525 | | 2005-06-24 |
T-20 With Anti-HIV Combination Therapy for Patients With Prior Anti-HIV Drug Treatment and/or Drug Resistance to Each of the Three Classes of Approved Anti-HIV Drugs
Enfuvirtide - HIV Infections | Phase 3 | Completed | Hoffmann-La Roche | 525 | | 2005-06-24 |
A Study of T-20 in HIV-Positive Adults
Enfuvirtide - HIV Infections | Phase 2 | Completed | Trimeris | 78 | | 2005-06-24 |
Study of Enfuvirtide in HIV-Positive Subjects
Fuzeon - HIV Infections, AIDS | Phase 1 | Completed | Trimeris | 26 | | 2005-06-24 |
Conditions studied
HIV Infections (12) · Acquired Immunodeficiency Syndrome (1)
Interventions
Enfuvirtide (11) · Integrase Inhibitors (1) · Ritonavir (1) · abacavir (1) · amprenavir (1) · efavirenz (1) · peptide T1249 (1)
Countries
United States (11) · Puerto Rico (3) · Australia (2) · Canada (2) · Belgium (1) · Germany (1) · Italy (1) · Netherlands (1) · Spain (1) · Sweden (1) · Switzerland (1) · United Kingdom (1)
Top investigators
Sam Hopkins (1)
Results publications
PMID 18474492, PMID 18771056